Related Experiment Video
Updated: Feb 11, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients
Viviana Nociti1,2, Marco Biolato3, Chiara De Fino1
1Multiple Sclerosis Center, Neuroscience Area, Neuroscience, Aging, Head and Neck and Orthopaedics Sciences Department, Fondazione Policlinico Universitario Gemelli, Catholic University of Sacred Heart, Rome, Italy.
Objectives:
High-dose pulsed methylprednisolone-related liver injury cases have been reported in the literature, but a prospective study in patients with multiple sclerosis (MS) has never been performed. The aim of this study was to evaluate the prevalence and severity of liver injury in patients with MS after pulsed methylprednisolone therapy.
Methods:
We performed a prospective observational single-center study on patients with MS treated with i.v. methylprednisolone 1,000 mg/day for 5 days. We tested the liver functionality before and 2 weeks after the treatment. In case of severe liver injury, defined according to "Hy's law," a comprehensive hepatologic workup was performed.
Results:
During a 12-month observation period, we collected data on 251 cycles of i.v. steroid treatment of 175 patients with MS. After excluding eight cycles presenting a basal alteration of the biochemical liver tests, we observed a prevalence of 8.6% of liver injury in MS patients treated with pulsed methylprednisolone for clinical and neuroradiological relapses. In 2.5% of the patients, the liver injury was severe according to Hy's law; after a comprehensive hepatologic workup, three of them received a diagnosis of drug-induced liver injury and the other three of autoimmune hepatitis.
Conclusions:
Liver injury after pulsed methylprednisolone therapy in patients with MS is not infrequent, and a close monitoring of aminotransferase level before treatment and 2 weeks later seems advisable.
Insights
Liver injury is a notable risk for multiple sclerosis (MS) patients receiving high-dose pulsed methylprednisolone. Monitoring liver function post-treatment is recommended to detect potential adverse effects.
Area of Science:
- Neurology
- Hepatology
- Pharmacology
Background:
- High-dose pulsed methylprednisolone is a common treatment for multiple sclerosis (MS) relapses.
- Previous reports suggest a link between this therapy and liver injury, but prospective data in MS patients are lacking.
Purpose of the Study:
- To prospectively evaluate the prevalence and severity of liver injury in multiple sclerosis patients undergoing pulsed methylprednisolone therapy.
Main Methods:
- A prospective observational study was conducted on 175 MS patients receiving 1,000 mg/day of intravenous methylprednisolone for 5 days.
- Liver function tests were performed before and two weeks after treatment.
- Severe liver injury was defined by Hy's law, prompting further hepatologic evaluation.
Main Results:
- Out of 251 treatment cycles, 8.6% of patients showed liver injury post-treatment.
- Severe liver injury, as per Hy's law, occurred in 2.5% of patients.
- Hepatologic workup identified drug-induced liver injury in three patients and autoimmune hepatitis in three others.
Conclusions:
- Liver injury is a significant concern in MS patients treated with pulsed methylprednisolone.
- Regular monitoring of aminotransferase levels before and two weeks after therapy is advisable.
Related Concept Videos
Pulse
The pulse serves as a clinical...
Pulse
Pulse Rate and its Significance
Pulse rate, often measured in beats per minute (bpm), reflects the heart rate (HR), which is influenced by numerous factors such as stress, physical activity, and hormonal changes. A normal resting adult pulse rate falls...
NMR Spectrometers: Radiofrequency Pulses and Pulse Sequences
Pulse Oximetry
Purpose
Average SpO2 values are greater than 95%. If the readings fall below 90%, it indicates that...
Regulation of Pulse
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...

